Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025
MWN-AI** Summary
Lucid Diagnostics Inc. (Nasdaq: LUCD), a cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), is set to host an investor conference call on September 8, 2025, at 8:30 AM ET. This call will address key developments stemming from the September 4 Contractor Advisory Committee (CAC) meeting concerning the reconsideration of the Local Coverage Determination (LCD) L39256. This determination relates to the use of Lucid's EsoGuard® Esophageal DNA Test, a crucial tool in detecting conditions that may lead to esophageal cancer.
EsoGuard® is specifically designed for individuals suffering from gastroesophageal reflux disease (GERD), also known as chronic heartburn, a condition that can increase the risk of developing esophageal precancer and cancer. The test is conducted through a noninvasive office procedure using the EsoCheck® Esophageal Cell Collection Device, the first of its kind to provide widespread, early detection.
Investors can join the call via a live webcast available on Lucid's investor relations website, or by dialing in through designated telephone numbers for U.S. and international listeners. A replay of the call will be accessible for 90 days post-event.
This investor call comes amidst a critical period of regulatory review and is essential for stakeholders interested in Lucid's advancements in cancer diagnostics and the market dynamics affecting its products. Given the potential risks and uncertainties involving regulatory acceptance and market conditions, the leadership at Lucid expects to provide insights into their strategy moving forward within the evolving healthcare landscape.
For continuous updates and information, stakeholders are encouraged to visit Lucid's investor site.
MWN-AI** Analysis
As Lucid Diagnostics prepares for its investor call on September 8, 2025, market participants should closely monitor developments surrounding the Contractor Advisory Committee (CAC) meeting held on September 4, 2025, which is crucial for its EsoGuard® Esophageal DNA Test and its potential Medicare coverage.
Lucid operates in a niche market focused on cancer prevention in patients with gastroesophageal reflux disease (GERD). Recent advancements and discussions surrounding Local Coverage Determination (LCD) L39256 could significantly impact its market position. The outcome of the CAC meeting may influence the reimbursement environment, essential for driving adoption of the EsoGuard test within clinical practices.
Key factors for investors to consider include the company's financial health, competitive landscape, and regulatory risks. Historically, Lucid has faced volatility in stock performance based on regulatory updates and clinical result disclosures. Given the ongoing efforts to secure Medicare coverage, a positive ruling from the CAC could propel Lucid's shares as it would enhance the test's accessibility to a broader patient population.
Additionally, the company’s innovative approach to non-invasive testing positions it favorably against traditional endoscope procedures. Ultimately, understanding the implications of the CAC's feedback on EsoGuard's clinical effectiveness and cost-effectiveness will be important for assessing its market viability.
Investors should tune into the conference call for insights on strategic direction, partnership opportunities, and any updates on funding requirements, as these elements are crucial for sustaining operational longevity. As always, close attention should be paid to the broader regulatory landscape, as fluctuations or delays could present both risks and opportunities within this evolving sector.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
Conference call scheduled for Monday, September 8 , at 8:30 AM ET to discuss September 4 MolDX Contractor Advisory Committee (CAC) meeting
NEW YORK , Sept. 5, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today announced it will host a conference call on Monday, September 8, 2025 , at 8:30 a.m. Eastern Time to discuss the September 4 Contractor Advisory Committee ("CAC") Meeting convened by MolDX-participating Medicare Administrative Contractors as part of the reconsideration of Local Coverage Determination (LCD) L39256, "MolDX: Molecular Testing for Detection of Upper Gastrointestinal Metaplasia, Dysplasia, Neoplasia," for Lucid's EsoGuard ® Esophageal DNA Test.
Webcast and Conference Call Details
Date : Monday, September 8, 2025
Time : 8:30 AM ET
Webcast : Click Here to Join
The webcast will also be available at the investor relations section of the Company's website at luciddx.com . Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Investor Call" to join.
Following the conclusion of the call, a replay will be available for 90 days on the Company's investor relations website.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. Lucid is focused on the millions of patients with GERD, also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard ® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck ® Esophageal Cell Collection Device - the first and only commercially available tools designed with the goal of preventing esophageal cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit luciddx.com and for more information about its parent company PAVmed, please visit pavmed.com .
Forward-Looking Statements
This press release includes forward-looking statements that involve risks and uncertainties. Forward-looking statements are any statements that are not historical facts. Such forward-looking statements, which are based upon the current beliefs and expectations of Lucid Diagnostics' management, are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. Risks and uncertainties that may cause such differences include, among other things, volatility in the price of Lucid Diagnostics' common stock; general economic and market conditions; the uncertainties inherent in research and development, including the cost and time required to advance Lucid Diagnostics' products to regulatory submission; whether regulatory authorities will be satisfied with the design of and results from Lucid Diagnostics' clinical and preclinical studies; whether and when Lucid Diagnostics' products are cleared by regulatory authorities; market acceptance of Lucid Diagnostics' products once cleared and commercialized; Lucid Diagnostics' ability to raise additional funding as needed; and other competitive developments. These factors are difficult or impossible to predict accurately and many of them are beyond Lucid Diagnostics' control. In addition, new risks and uncertainties may arise from time to time and are difficult to predict. For a further list and description of these and other important risks and uncertainties that may affect Lucid Diagnostics' future operations, see Part I, Item 1A, "Risk Factors," in Lucid Diagnostics' most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, as the same may be updated in Part II, Item 1A, "Risk Factors" in any Quarterly Report on Form 10-Q filed by Lucid Diagnostics after its most recent Annual Report. Lucid Diagnostics disclaims any intention or obligation to publicly update or revise any forward-looking statement to reflect any change in its expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.
SOURCE Lucid Diagnostics
FAQ**
Can Lucid Diagnostics Inc. (LUCD) provide insights into the outcomes of the September 4 Contractor Advisory Committee (CAC) meeting and how it may impact the reimbursement landscape for the EsoGuard® test?
What specific data or findings from recent studies does Lucid Diagnostics Inc. (LUCD) plan to present during the call that support the efficacy of the EsoGuard® Esophageal DNA Test?
How does Lucid Diagnostics Inc. (LUCD) anticipate the potential changes to the Local Coverage Determination (LCD) L39256 will affect accessibility and adoption of its EsoGuard® test among healthcare providers and patients?
What are Lucid Diagnostics Inc. (LUCD)'s future plans for expanding its product lineup or pipeline in the cancer prevention diagnostic space following the discussions from the CAC meeting?
**MWN-AI FAQ is based on asking OpenAI questions about Lucid Diagnostics Inc. (NASDAQ: LUCD).
NASDAQ: LUCD
LUCD Trading
-1.07% G/L:
$1.385 Last:
147,261 Volume:
$1.41 Open:
